Postmarketing Study for Determine Performance of the SIGMA HP® PARTIAL KNEE SYSTEM
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a postmarketing study to assess the overall performance and survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis Post-traumatic Arthritis Gout Pseudo-gout |
Device: SIGMA HP PARTIAL KNEE |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Non-comparative, Multicentre, Multinational Study to Determine the Performance & Survivorship of the SIGMA HP® PARTIAL KNEE SYSTEM. |
- Survivorship (revision) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]Kaplan Meier Survival analysis at 3 years (based on revision of the femoral or tibial components)
- Survivorship [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: Yes ]Survival analyses at each post-operative assessment.
- Knee Society Score [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: No ]Mean change from baseline (pre-op) to each post-operative assessment
- KOOS [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: No ]Mean change from baseline (pre-op) to each post-operative assessment.
- HAAS [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: No ]Mean change from baseline (pre-op) to each post-operative assessment.
- Kujala Score [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: No ]Mean change from baseline (pre-op) to each post-operative assessment.
- Oxford Knee Score [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: No ]Mean change from baseline (pre-op) to each post-operative assessment.
- EQ-5D [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: No ]Mean change from baseline (pre-op) to each post-operative assessment.
- Radiographic Analysis [ Time Frame: 1, 2, 5 and 10 years ] [ Designated as safety issue: Yes ]Change from 6 week post-operative assessment at all post-operative timepoints to identify the number of implants that are 'at risk'.
| Estimated Enrollment: | 200 |
| Study Start Date: | November 2011 |
| Estimated Study Completion Date: | April 2022 |
| Estimated Primary Completion Date: | April 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Sigma HP Partial Knee |
Device: SIGMA HP PARTIAL KNEE
SIGMA HP PARTIAL KNEE
Other Names:
|
Detailed Description:
The purpose of this study is to collect more information about a particular type of joint replacement for people with degenerative diseases of the knee such as osteoarthritis. This type of knee replacement is called the Sigma HP® Partial Knee System and it is made by a company called DePuy International. Orthopaedic surgeons have been using this type of knee replacement for about two years. The aim of this study is to measure how this particular type of knee replacement performs over a ten year period.
Osteoarthritis (OA) is the most common form of arthritis and can affect any joint in the body. It occurs due to some type of trauma to the joint, a repeated injury to the joint, or simply due to ageing and 'wearing' of cartilage which covers and cushions the inside of a joint.
There are a number of different ways to treat OA and other degenerative diseases of the knee but commonly people have all or part of their knee joint replaced with artificial parts. The knee is made up of three compartments and arthritis can affect any number of these compartments. The Sigma HP® Partial Knee System allows a surgeon to replace only the compartments that are affected by the arthritis rather than replacing all the compartments which is what would happen in a total knee replacement. Replacing only the damaged areas maintains more of your natural knee and we think this means that more of the knee's natural movement and function can be restored. The surgery for a partial knee replacement is less invasive than for a total knee replacement and this should mean there is potential for a faster recovery.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male or female subjects, aged at least 21 years.
- Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
- Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
- Subject has non-inflammatory degenerative joint disease (NIDJD), including: OA, posttraumatic arthritis, avascular necrosis and chondrocalcinosis.
- Subject has a functional stable knee.
- Subject, in the opinion of the Investigator, is suitable for either a single or bicompartmental knee replacement.
Subject meets the following selected radiographic parameters:
- X-ray evaluation confirms the presence of NIDJD
- Disease location: 1 to 2 compartments, maximum. Disease can be present in the patellofemoral compartment, the medial tibiofemoral compartment, lateral tibiofemoral compartments alone or in any two compartments.
- Disease severity: Kellgren and Lawrence44 Grade II or greater for all compartments replaced.
Exclusion Criteria:
- Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
- Women who are pregnant.
- Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
- Subjects who have participated in a clinical investigation with an investigational product in the last 3 months.
- Subjects who are currently involved in any injury litigation claims.
- Multiple joint involvement that will compromise rehabilitation (for example: advanced hip, ankle or spine disease).
- Known to be a prisoner, mentally incompetent, an alcohol / drug abuser, involved in medical-legal case or worker's compensation
- Previous knee arthroplasty (any type) in any one of the three compartments of the knee.
- Requires more than a lateral soft tissue release or an anterior cruciate ligament reconstruction.
- Uncorrectable anatomical tibio-femoral angle.
- Bone deficiency requiring structural bone grafts to support the implants.
- Previous patellectomy.
- For Subjects indicated for a PFA, Subject has uncorrected patella baja (Caton-Deschamps ratio less than or equal to 0.6).
- Tri-compartmental disease process (patella-femoral, medial tibio-femoral and lateral tibio-femoral).
- Active bacterial infection that may spread to other areas of the body (e.g., osteomyelitis, pyogenic infection of knee joint, urinary tract infection, etc.).
- Significant neurological or musculoskeletal deformity or a disease that may affect gait or weight bearing, (e.g., muscular dystrophy, multiple sclerosis, amputation).
- Known allergy to implant materials.
Contacts and Locations| Contact: Sue Kemp, Ph.D | +44113 3877804 | skemp1@its.jnj.com |
| France | |
| CHU La Cavale Blanche | Withdrawn |
| Brest, France | |
| Germany | |
| Asklepios Westklinikum Hamburg | Not yet recruiting |
| Hamburg, Germany | |
| Principal Investigator: W Herzberg, Dr. med. | |
| Krankenhaus Maerkisch-Oderland | Not yet recruiting |
| Wriezen, Germany | |
| Italy | |
| Orthopedic Institute IRCCS Galeazzi | Withdrawn |
| Milan, Italy | |
| CDC, Citta di Palma | Withdrawn |
| Parma, Italy | |
| Switzerland | |
| Schulthess Klinik | Recruiting |
| Zurich, Switzerland | |
| Principal Investigator: S Preiss | |
| United Kingdom | |
| Harrogate District Hospital | Withdrawn |
| Harrogate, United Kingdom, HG2 7SX | |
| Clifton Park NHS Treatment Centre | Recruiting |
| York, United Kingdom, YO30 5RA | |
| Contact: A Gibbon, BSc MBBS FRCS(Orth) | |
| Principal Investigator: A Gibbon, BSc MBBS FRCS(Orth) | |
| Principal Investigator: | Mr A Gibbon, BSc MBBS FRCS(Orth) | Clifton Park NHS Treatment Centre |
More Information
No publications provided
| Responsible Party: | DePuy International |
| ClinicalTrials.gov Identifier: | NCT01529099 History of Changes |
| Other Study ID Numbers: | CT10/01 |
| Study First Received: | December 6, 2011 |
| Last Updated: | April 4, 2013 |
| Health Authority: | United Kingdom: Department of Health United Kingdom: Food Standards Agency United Kingdom: Medicines and Healthcare Products Regulatory Agency United Kingdom: National Health Service United Kingdom: National Institute for Health Research United Kingdom: Research Ethics Committee Switzerland: Ethikkommission Switzerland: Federal Office of Public Health Switzerland: Laws and standards Switzerland: Swissmedic Italy: Ethics Committee Italy: Ministry of Health Italy: National Bioethics Committee Italy: National Institute of Health Italy: National Monitoring Centre for Clinical Trials - Ministry of Health Italy: The Italian Medicines Agency Germany: Ethics Commission Germany: Federal Institute for Drugs and Medical Devices Germany: Federal Ministry of Education and Research Germany: Federal Ministry of Food, Agriculture and Consumer Protection Germany: Federal Office for Radiation Protection Germany: German Institute of Medical Documentation and Information Germany: Ministry of Health Germany: Ministry of Work, Health and Social Affairs in North Rhine-Westph Germany: Paul-Ehrlich-Institut Germany: The Bavarian State Ministry of the Environment and Public Health France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) France: Comité consultatif sur le traitement de l'information en matière de recherche dans le domaine de la santé France: Committee for the Protection of Personnes France: Conseil National de l'Ordre des Médecins France: Direction Générale de la Santé France: French Data Protection Authority France: Haute Autorité de Santé Transparency Commission France: Institutional Ethical Committee France: Ministry of Health France: Ministère de l'Enseignement supérieur et de la Recherche France: National Consultative Ethics Committee for Health and Life Sciences France: The Commission nationale de l’informatique et des libertés |
Keywords provided by DePuy International:
|
Osteoarthritis Knee Knee replacement Knee implant Knee arthroplasty Unicompartmental Primary Partial |
Patellofemoral Medial Lateral Bicompartmental Cemented Post-traumatic arthritis of the tibio-femoral and/or patellofemoral articular surfaces History of Gout or pseudo-gout. |
Additional relevant MeSH terms:
|
Arthritis Gout Osteoarthritis Chondrocalcinosis Joint Diseases Musculoskeletal Diseases |
Rheumatic Diseases Purine-Pyrimidine Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013